UNASSIGNED: The patients who were diagnosed definitely as having DSWPD by board-certified physicians specialized in sleep medicine and started to receive strategically timed ramelteon medications after the diagnosis were included. Data on the initial ramelteon dose and follow-up duration (up to 24 months) were collected retrospectively. Patients with treatment discontinuation, changes in ramelteon dose, or the addition of other sleep-related medications were considered dropouts. Kaplan-Meier estimates, log-rank tests, and Cox regression analyses were performed.
UNASSIGNED: Overall, 373 patients were analyzed. The findings revealed that the 2 mg dose of ramelteon was associated with a lower dropout rate compared to the other doses (8 mg, 4 mg, and 1 mg). The dropout rate for the 2 mg group was estimated to have a hazard ratio (HR) of 0.5762 when compared with the 8 mg dose group. Sex did not reveal a significant HR, whereas older age exhibited a small but significant HR (0.9858).
UNASSIGNED: For achieving better adherence, a dosing regimen of strategically timed 2 mg ramelteon may be the best for the treatment of DSWPD. The therapeutic dose window for better adherence seems to center approximately 2 mg of ramelteon. Furthermore, caution should be exercised when treating younger patients to prevent dropouts.
■被专门研究睡眠医学的董事会认证医师明确诊断为患有DSWPD的患者,并在诊断后开始接受战略性定时的ramelteon药物治疗。回顾性收集了有关初始ramelteon剂量和随访时间(长达24个月)的数据。停止治疗的患者,拉美脱剂量的变化,或添加其他睡眠相关药物被认为是辍学。Kaplan-Meier估计,对数秩测试,并进行Cox回归分析。
■总的来说,对373例患者进行分析。研究结果表明,与其他剂量(8mg,4毫克,和1毫克)。当与8mg剂量组相比时,2mg组的脱落率估计具有0.5762的风险比(HR)。性别没有显示重要的人力资源,而年龄较大的表现出较小但显着的HR(0.9858)。
■为了获得更好的依从性,策略性定时给药2mgramelteon可能是治疗DSWPD的最佳方案.更好的依从性的治疗剂量窗口似乎以大约2mg的ramelteon为中心。此外,治疗年轻患者时应谨慎,以防止辍学。